Locally advanced and metastatic endometrial cancer: Current and emerging therapies.

[en] Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.

Disciplines :

Oncology

Author, co-author :

Salmon, Alixe ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

LEBEAU, Alizée ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

Streel, Sylvie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

Dheur, Adriane; CHU Liège - Centre Hospitalier Universitaire de Liège [BE] > Service de gynécologie-obstétrique

Schoenen, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique

Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR) ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique

Gonne, Elodie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

Kridelka, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique

Kakkos, Athanasios ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique

Gennigens, Christine ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Locally advanced and metastatic endometrial cancer: Current and emerging therapies.

Publication date :

22 June 2024

Journal title :

Cancer Treatment Reviews

ISSN :

0305-7372

eISSN :

1532-1967

Publisher :

Elsevier BV, Netherlands

Volume :

129

Pages :

102790

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S030573722400118X?httpAccept=text/xml

Available on ORBi :

since 08 July 2024

Statistics

Number of views

30 (13 by ULiège)

Number of downloads

13 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin mai 71:3 (2021), 209–249.
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D.A., Westin, S.N., Aoki, D., et al. Endometrial cancer. Nat Rev Dis Primer, 7(1), 2021, 88.
Restaino, S., Paglietti, C., Arcieri, M., Biasioli, A., Della Martina, M., Mariuzzi, L., et al. Management of patients diagnosed with endometrial cancer: comparison of guidelines. Cancers, 15(4), 2023, 1091.
Garmezy, B., Gheeya, J., Lin, H.Y., Huang, Y., Kim, T., Jiang, X., et al. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol déc, 6, 2022, e2100267.
Wang, F., Zhao, Q., Wang, Y.N., Jin, Y., He, M.M., Liu, Z.X., et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 5:10 (Oct 2019), 1504–1506.
Oaknin, A., Gladieff, L., Martínez-García, J., Villacampa, G., Takekuma, M., Giorgi, U.D., et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 403:10421 (6 janv 2024), 31–43.
Oaknin, A., Gilbert, L., Tinker, A.V., Brown, J., Mathews, C., Press, J., et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer, 10(1), 21 janv 2022;, e003777.
Lakhani, N., Cosman, R., Banerji, U., Rasco, D., Tomaszewska-Kiecana, M., Garralda, E., et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101). ESMO Open, 9(4), 21 févr 2024, 102254.
Berton D, Pautier P, Lorusso D, Gennigens C, Gladieff L, Kryzhanivska A, et al. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecol Oncol 2024;186:191‑8.
Slomovitz B, Monk B, Moxley K, Ghali N, Sokol JF, Tian C, et al. A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO). J Immunother Cancer [Internet]. 1 nov 2020 [cité 19 avr 2024];8(Suppl 3). Disponible sur: https://jitc.bmj.com/content/8/Suppl_3/A212.
Powell, M.A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol Off J Eur Soc Med Oncol, 10, 2024 S0923–7534(24)00721-X.
Eskander, R.N., Sill, M.W., Beffa, L., Moore, R.G., Hope, J.M., Musa, F.B., et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 388:23 (8 juin 2023), 2159–2170.
Westin, S.N., Moore, K., Chon, H.S., Lee, J.Y., Thomes Pepin, J., Sundborg, M., et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol 42:3 (20 janv 2024), 283–299.
Mirza MR, Coleman RL, Hanker L, Slomovitz B, Valabrega G, DeMars L, et al. ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). Ann Oncol. 1 sept 2021;32:S770‑1.
Garg, K., Leitao, M.M., Wynveen, C.A., Sica, G.L., Shia, J., Shi, W., et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol janv 23:1 (2010), 80–92.
Tresa, A., Sambasivan, S., Rema, P., Dinesh, D., Sivaranjith, J., Nair, S.P., et al. Clinical profile and survival outcome of endometrial cancer with p53 mutation. Indian J Surg Oncol sept 13:3 (2022), 580–586.
Liu, J., Oza, A.M., Colombo, N., Oaknin, A., ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 32:1 (2022), 89–92.
Meric-Bernstam, F., Chalsani, P., Mamdani, H., Zheng, C., Viana, M., Lambersky, R., et al. Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Cancer Res, 82(12_Supplement), 2022, CT029.
Muñoz-Fontela, C., Mandinova, A., Aaronson, S.A., Lee, S.W., Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 16:12 (2016), 741–750.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, et al. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Ann Oncol [Internet]. 3 mai 2024 [cité 14 juin 2024]; Disponible sur: https://www.sciencedirect.com/science/article/pii/S0923753424001285.
Li, L., Ng, D.S.W., Mah, W.C., Almeida, F.F., Rahmat, S.A., Rao, V.K., et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death Differ 22:7 (2015), 1081–1093.
Wellenstein, M.D., Coffelt, S.B., Duits, D.E.M., van Miltenburg, M.H., Slagter, M., de Rink, I., et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572:7770 (2019), 538–542.
Zhang, W.W., Li, L., Li, D., Liu, J., Li, X., Li, W., et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther févr 29:2 (2018), 160–179.
Su, X., Chen, W.J., Xiao, S.W., Li, X.F., Xu, G., Pan, J.J., et al. Effect and safety of recombinant adenovirus-p53 transfer combined with radiotherapy on long-term survival of locally advanced cervical cancer. Hum Gene Ther 27:12 (2016), 1008–1014.
Ray-Coquard, I., Monk, B.J., Lorusso, D., Mahdi, H., Upadhyay, V., Graul, R., et al. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma. Int J Gynecol Cancer 33:12 (2023), 1943–1949.
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, et al. Safety and efficacy of the mTOR inhibitor, vistusertib, combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. JAMA Oncol 2022;8(7):1001‑9.
Mirza, M.R., Bjørge, L., Marmé, F., Christensen, R.D., Gil-Martin, M., Auranen, A., et al. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): ESMO Virtual Congress 2020. Ann Oncol, 31(Suppl. 4), 2020, S1160.
Colon-Otero, G., Zanfagnin, V., Hou, X., Foster, N.R., Asmus, E.J., Wahner Hendrickson, A., et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open, 5(5), Oct 2020, e000926.
Konstantinopoulos, P.A., Lee, E.K., Xiong, N., Krasner, C., Campos, S., Kolin, D.L., et al. A phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer. J Clin Oncol Off J Am Soc Clin Oncol 41:3 (2023), 599–608.
Bogani, G., Monk, B.J., Coleman, R.L., Vergote, I., Oakin, A., Ray-Coquard, I., et al. Selinexor in patients with advanced and recurrent endometrial cancer. Curr Probl Cancer, 47(6), 2023, 100963.
Makker V, Perez-Fidalgo JA, Bergamini A, Spitz DL, Van Gorp T, Sehouli J, et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. J Clin Oncol 2022;40(16_suppl):5511.
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Gorp TV, Sehouli J, et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202‑11.
Vergote I, Mirza MR, Coleman RL, Perez-Fidalgo JA, Monk BJ, Valabrega G, et al. ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma. J Clin Oncol 2023;41(16_suppl):TPS5627‑TPS5627.
Yoon H, Suh DH, Kim K, No JH, Kim YB, Kim H. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group. Gynecol Oncol 2024;184:132‑8.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, et al. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol 2023;172:82‑91.
Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 2016;35(17):2197‑207.
Roškar, L., Roškar, I., Rižner, T.L., Smrkolj, Š., Diagnostic and therapeutic values of angiogenic factors in endometrial cancer. Biomolecules, 12(1), 2022, 7.
Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 2011;29(16):2259‑65.
Simpkins, F., Drake, R., Escobar, P.F., Nutter, B., Rasool, N., Rose, P.G., A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136:2 (2015), 240–245.
Coleman, R.L., Sill, M.W., Lankes, H.A., Fader, A.N., Finkler, N.J., Hoffman, J.S., et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 127:3 (2012), 538–543.
Moore, K.N., Sill, M.W., Tenney, M.E., Darus, C.J., Griffin, D., Werner, T.L., et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol 138:3 (2015), 513–518.
Bender, D., Sill, M.W., Lankes, H.A., Reyes, H.D., Darus, C.J., Delmore, J.E., et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:3 (2015), 507–512.
Campos, S.M., Brady, W.E., Moxley, K.M., O'Cearbhaill, R.E., Lee, P.S., DiSilvestro, P.A., et al. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 133:3 (2014), 537–541.
Castonguay, V., Lheureux, S., Welch, S., Mackay, H.J., Hirte, H., Fleming, G., et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 134:2 (2014), 274–280.
Lheureux S, Matei D, Konstantinopoulos PA, Block MS, Jewell A, Gaillard S, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020;38(15_suppl):6010.
Powell, M.A., Sill, M.W., Goodfellow, P.J., Benbrook, D.M., Lankes, H.A., Leslie, K.K., et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:1 (Oct 2014), 38–43.
Dizon, D.S., Sill, M.W., Schilder, J.M., McGonigle, K.F., Rahman, Z., Miller, D.S., et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:3 (2014), 441–445.
Konecny, G.E., Finkler, N., Garcia, A.A., Lorusso, D., Lee, P.S., Rocconi, R.P., et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 16:6 (2015), 686–694.
Vergote, I., Powell, M.A., Teneriello, M.G., Miller, D.S., Garcia, A.A., Mikheeva, O.N., et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol 156:3 (2020), 575–582.
Makker V, Aghajanian C, Cohn AL, Romeo M, Bratos R, Brose MS, et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111/KEYNOTE-146): long-term efficacy and safety update. J Clin Oncol Off J Am Soc Clin Oncol 2023;41(5):974‑9.
Marth, C., Tarnawski, R., Tyulyandina, A., Pignata, S., Gilbert, L., Kaen, D., et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 32:1 (2022), 93–100.
Slomovitz, B.M., Chelariu-Raicu, A., Schmeler, K.M., Lu, K.H., Gershenson, D.M., Wolf, J., et al. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 30:11 (Nov 2020), 1733–1737.
Leslie, K.K., Sill, M.W., Lankes, H.A., Fischer, E.G., Godwin, A.K., Gray, H., et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127:2 (Nov 2012), 345–350.
Leslie, K.K., Sill, M.W., Fischer, E., Darcy, K.M., Mannel, R.S., Tewari, K.S., et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129:3 (2013), 486–494.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol Off J Am Soc Clin Oncol 2008;26(26):4319‑25.
Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol Off J Am Soc Clin Oncol 2006;24(15):2376‑85.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res Off J Am Assoc Cancer Res 2020;26(15):3928‑35.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol Off J Am Soc Clin Oncol 2023;41(15):2789‑99.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol Off J Am Soc Clin Oncol 2024;42(1):47‑58.
Banerji, U., van Herpen, C.M.L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20:8 (2019), 1124–1135.
Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2012;18(21):5856‑64.
Matulonis, U., Vergote, I., Backes, F., Martin, L.P., McMeekin, S., Birrer, M., et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol févr 136:2 (2015), 246–253.
Makker V, Recio FO, Ma L, Matulonis U, Lauchle JO, Parmar H, et al. A Multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 2016;122(22):3519‑28.
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group. Br J Cancer 2017;116(3):303‑9.
Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, et al. Phase II, 2-Stage, 2-Arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer 2020;147(2):413‑22.
Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(31):3576‑82.
Tsoref, D., Welch, S., Lau, S., Biagi, J., Tonkin, K., Martin, L.A., et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135:2 (Nov 2014), 184–189.
Han, S.N., Oza, A., Colombo, N., Oaknin, A., Raspagliesi, F., Wenham, R.M., et al. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer. Gynecol Oncol 178 (Nov 2023), 110–118.
Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, et al. A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116(23):5415‑9.
Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer 2020;126(6):1274‑82.
Del Campo, J.M., Birrer, M., Davis, C., Fujiwara, K., Gollerkeri, A., Gore, M., et al. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol 142:1 (2016), 62–69.
Alvarez, E.A., Brady, W.E., Walker, J.L., Rotmensch, J., Zhou, X.C., Kendrick, J.E., et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 129:1 (2013), 22–27.
Stringer, E.M., Fleming, G.F., Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma. Oncol Hematol Rev 9:1 (2013), 41–44.
Slomovitz, B.M., Filiaci, V.L., Walker, J.L., Taub, M.C., Finkelstein, K.A., Moroney, J.W., et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol 164:3 (2022), 481–491.
Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, et al. Everolimus, Letrozole, and Metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study. Clin Cancer Res Off J Am Assoc Cancer Res 2020;26(3):581‑7.
Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 2023;8(1):1‑25.
Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study - PMC [Internet]. [cité 5 avr 2024]. Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922584/.
Santin, A.D., Filiaci, V., Bellone, S., Ratner, E.S., Mathews, C.A., Cantuaria, G., et al. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep, 31, 2020, 100532.
Sideris, M., Emin, E.I., Abdullah, Z., Hanrahan, J., Stefatou, K.M., Sevas, V., et al. The Role of KRAS in Endometrial Cancer: A Mini-Review. Anticancer Res 39:2 (2019), 533–539.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383(13):1207‑17.
Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, et al. Phase II trial of cabozantinib in recurrent/metastatic endometrial cancer: a study of the princess margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res Off J Am Assoc Cancer Res 2020;26(11):2477‑86.
Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol Off J U S Can Acad Pathol Inc 2023;36(3):100049.
Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71(21):6718‑27.
Mullen, J., Kato, S., Sicklick, J.K., Kurzrock, R., Targeting ARID1A mutations in cancer. Cancer Treat Rev, 100, Nov 2021, 102287.
Miller, R.E., Brough, R., Bajrami, I., Williamson, C.T., McDade, S., Campbell, J., et al. Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol Cancer Ther 15:7 (2016), 1472–1484.
Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71.
Jackson, C.G., Moore, K.N., Cantrell, L., Erickson, B.K., Duska, L.R., Richardson, D.L., et al. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol 166:1 (2022), 44–49.
Banerjee, S., Leary, A., Stewart, J.R., Dewan, M., Lheureux, S., Clamp, A.R., et al. 34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial. ESMO Open, 8(1), 2023, 100814.
Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol 2022;165(2):223‑9.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. Nat Commun 2023;14(1):1452.
You B, Leary A, Rodrigues M, Follana P, Abdeddaim C, Joly F, et al. Abstract CT005: Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial. Cancer Res 2022;82(12_Supplement):CT005.
Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev 2022;110:102461.
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol Off J Am Soc Clin Oncol 2018;36(32):3223‑30.
Kyi C, Rubinstein MM, Shah P, Zhou Q, Iasonos A, Liu Y, et al. A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056). J Clin Oncol 2022;40(16_suppl):5589.
Scaranti, M., Cojocaru, E., Banerjee, S., Banerji, U., Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol 17:6 (2020), 349–359.
Call JA, Anderson I, Winer I, Orr D, Yeku O, Richardson DL, et al. 708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors. J Immunother Cancer [Internet]. 1 nov 2023 [cité 5 avr 2024];11(Suppl 1). Disponible sur: https://jitc.bmj.com/content/11/Suppl_1/A803.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med 2023;389(23):2162‑74.
Bogani, G., Monk, B.J., Powell, M.A., Westin, S.N., Slomovitz, B., Moore, K.N., et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 35:5 (2024), 414–428.